Chemotherapy-Induced Peripheral Neuropathy is a frequent, dose-dependent complication of anticancer drugs, including platinum, taxanes, epothilones, vinca alkaloids, and newer agents.
&nbsp;
Chemotherapy-Induced Peripheral Neuropathy Epidemiological Segmentation 
The Epidemiological Segmentation of Chemotherapy-Induced Peripheral Neuropathy in 7MM from 2018 to 2030 is segmented as:-
<ul>
<li>Total Incident Population of Chemotherapy-Induced Peripheral Neuropathy</li>
<li>Incident Population of CIPN by Chemotherapeutic Agents</li>
<li>Severity Specific Incidence of Chemotherapy-Induced Peripheral Neuropathy</li>
<li>Incident Population of CIPN by Cancer Type&nbsp;</li>
</ul>
&nbsp;
<a style="color: #0047b2;" href="https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Chemotherapy-Induced Peripheral Neuropathy Epidemiology</a>
<ul>
<li>The total prevalent population of Chemotherapy-Induced Peripheral Neuropathy in 7MM in 2018 was 1,522,437 </li>
<li>The total number of CIPN prevalent cases in the United States was found to be 635,154.</li>
<li>Germany had a total of 170,283 Chemotherapy-Induced Peripheral Neuropathy cases.</li>
<li>The total number of CIPN cases in the United Kingdom was estimated to be 126,282.</li>
<li>The total Chemotherapy-Induced Peripheral Neuropathy prevalent cases in Spain were 76,599.</li>
<li>In Japan, the total number of CIPN prevalent cases was observed to be 270,556.</li>
</ul>
&nbsp;
<a style="color: #0047b2;" href="https://www.delveinsight.com/report-store/cipn-market" target="_blank" rel="noopener noreferrer">Chemotherapy-Induced Peripheral Neuropathy Market</a>
The therapeutic market size of Chemotherapy-Induced Peripheral Neuropathy in 7MM in 2020 was USD 1,435.67 million.
&nbsp;
Chemotherapy-Induced Peripheral Neuropathy Market Drivers
<ul>
<li>Increasing emerging therapies</li>
<li>Increasing awareness</li>
</ul>
&nbsp;
Chemotherapy-Induced Peripheral Neuropathy Market Barriers
<ul>
<li>No standard assessment</li>
<li>Current therapy limitations</li>
<li>Herbal remedies</li>
<li>Clinical understanding&nbsp;</li>
</ul>
&nbsp;
<a style="color: #0047b2;" href="https://www.delveinsight.com/report-store/chemotherapy-induced-peripheral-neuropathy-cipn-pipeline-insight" target="_blank" rel="noopener noreferrer">Chemotherapy-Induced Peripheral Neuropathy Emerging Drugs</a>
The emerging drugs of the CIPN market are:
<ul>
<li>SP-04 (PledOx)</li>
<li>Tetrodotoxin or TTX</li>
<li>E-52862</li>
<li>ART-123 (Thrombomodulin alfa)</li>
<li>MN-166 (Ibudilast)</li>
<li>KRN 5500</li>
<li>Niagen</li>
<li>TRK-750</li>
</ul>
and many others.
&nbsp;
Chemotherapy-Induced Peripheral Neuropathy Key Players
The key players in the CIPN market are:
<ul>
<li>Solasia/PledPharma</li>
<li>WEX Pharmaceuticals</li>
<li>Laboratorios Dr. Esteve S.A. (ESTEVE)</li>
<li>Asahi Kasei Pharma</li>
<li>MediciNova</li>
<li>DARA BioSciences</li>
<li>ChromaDex</li>
<li>Toray Industries&nbsp;</li>
</ul>
and many others.
&nbsp;
Follow our blogs to get more insights into <a style="color: #0047b2;" href="https://www.delveinsight.com/blog/chemotherapy-induced-peripheral-neuropathy-market-trends" target="_blank" rel="noopener noreferrer">Chemotherapy-induced Peripheral Neuropathy market landscape</a>

Chemotherapy Induced Peripheral Neuropathy Market

Chemotherapy Induced Peripheral Neuropathy (CIPN) Market

Chemotherapy-Induced Peripheral Neuropathy Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape